La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

OliX Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 0/6

OliX Pharmaceuticals ha un patrimonio netto totale di ₩26.4B e un debito totale di ₩44.0B, che porta il suo rapporto debito/patrimonio netto a 166.8%. Le sue attività totali e le sue passività totali sono rispettivamente ₩92.5B e ₩66.1B.

Informazioni chiave

166.8%

Rapporto debito/patrimonio netto

₩44.02b

Debito

Indice di copertura degli interessi	n/a
Contanti	₩24.44b
Patrimonio netto	₩26.40b
Totale passività	₩66.10b
Totale attività	₩92.50b

Aggiornamenti recenti sulla salute finanziaria

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

Jul 22

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Apr 13

Recent updates

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

Jul 22

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

Jun 25

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Apr 13

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Feb 17

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { A226950 di ₩28.3B ) non coprono le sue passività a breve termine ( ₩31.3B ).

Passività a lungo termine: Le attività a breve termine di A226950 ( ₩28.3B ) non coprono le sue passività a lungo termine ( ₩34.8B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 74.2% ) di A226950 è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di A226950 è aumentato da 0% a 166.8% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: A226950 ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: A226950 ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 27 % ogni anno

OliX Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Recent updates

Second quarter 2024 earnings released: ₩578 loss per share (vs ₩646 loss in 2Q 2023)

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

New minor risk - Share price stability

OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors

Full year 2023 earnings released: ₩1,324 loss per share (vs ₩1,877 loss in FY 2022)

OliX Pharmaceuticals, Inc Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug

OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration

Third quarter 2023 earnings released: ₩346 loss per share (vs ₩385 loss in 3Q 2022)

New minor risk - Shareholder dilution

OliX Pharmaceuticals, Inc. Announces First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia

OliX Pharmaceuticals, Inc. Presents Preclinical Data Showing Synergistic Weight Loss from Anti-NASH siRNA and Semaglutide Combination Treatment

Full year 2022 earnings released: ₩1,877 loss per share (vs ₩2,088 loss in FY 2021)

Olix Pharmaceuticals Publishes Preclinical Research Demonstrating Olx104c’S Potential as an Effective Treatment for Hair Loss

No independent directors

OliX Pharmaceuticals, Inc Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-Related Macular Degeneration

OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial

Olix Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of Olx101a in Patients with Hypertrophic Scars

OliX Pharmaceuticals, Inc announced that it has received KRW 57 billion in funding from a group of investors

OliX Pharmaceuticals, Inc announced that it expects to receive KRW 15.000139 billion in funding from Shinhan Capital Co., Ltd. and other investors

Olix Pharmaceuticals,Inc Identifies Effective Inhibition of Target Gene Expression and Delivery of Candidate to Brain for CNS Therapeutics

No independent directors

OliX Pharmaceuticals,Inc Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate

OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Improved Intracellular Delivery Platform Technology for RNAi Therapeutics

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Full year 2020 earnings released: ₩1,474 loss per share (vs ₩1,102 loss in FY 2019)

New 90-day low: ₩38,800

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

OliX Pharmaceuticals, Inc. Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

New 90-day high: ₩58,500

Third quarter 2020 earnings released: ₩639 loss per share

New 90-day high: ₩77,000

OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial for Hypertrophic Scars

OliX Pharmaceuticals, Inc. Announces Expansion of Collaboration with Laboratoires Théa to Develop SiRNA Therapeutics for Ophthalmic Diseases

New 90-day high: ₩64,100

OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial

New 90-day high - ₩58,600

First half earnings released

New 90-day high - ₩53,700

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane